Neither CP CML nor BCR-ABL TKIs induces clinically significant immune suppression, and there is no evidence that CP CML patients are at greater risk of complications by SARS-CoV-2 than the normal community. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.